CA-ARCULES
11.2.2020 17:32:06 CET | Business Wire | Press release
Arcules , leading innovators in integrated video and access control cloud services, today announced the commercial availability of the Arcules-XProtect Hybrid™ VMS Solution in North America and Europe. The solution represents a combination of the Arcules Video Surveillance as a Service (VSaaS) integrated with Milestone XProtect Corporate on-premise video management software (VMS). The result is a flexible and feature-rich hybrid video surveillance solution ideal for organizations looking to centralize their dispersed video surveillance operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005274/en/
With Arcules-XProtect Hybrid VMS Solution, Milestone XProtect customers can deploy remote sites quickly, with minimal IT resources and downtime while still benefiting from the strong capabilities of XProtect on-premise VMS. Additionally, Arcules’ intuitive platform provides sites and cameras connected to Arcules VSaaS an underlying cloud infrastructure such as compatibility between sites, low video latency, data encryption, redundancy, streamlined maintenance with automatic updates, and easy onboarding.
“Milestone resellers and end customers are planning their deployment to take advantage of the many benefits of cloud computing. This integration gives Milestone XProtect Corporate customers a new hybrid cloud computing deployment option,” said Bjørn Skou Eilertsen, CTO of Milestone Systems. “The typical Milestone XProtect Corporate user has many branch offices of different sizes and locations. Enabling this hybrid deployment option can allow them to simplify large scale deployments. After the Arcules system is Interconnected the user can utilize these Arcules connected cameras with the advanced XProtect Corporate product capabilities.”
The Arcules-XProtect Hybrid VMS Solution uses Milestone Interconnect™ technology to combine the hyper-scalability and licensing flexibility of Arcules cloud service with the feature-rich video management functions of XProtect Corporate. The combination of these advanced technologies provides uniform access to live video, recordings and alarms across cameras physically connected on-premise and virtually connected via the Arcules cloud, through XProtect Smart Client, XProtect Smart Wall, and the web and mobile clients.
Organizations with distributed locations such as healthcare, retail, corporate campuses and education, and utility environments all benefit from high-performance cloud services to provide real-time insight in the event of an incident in remote areas. The Arcules-XProtect Hybrid VMS Solution also adds value to monitoring stations and law enforcement organizations that use XProtect Corporate as their VMS platform. Such organizations can now access cameras and customers subscribed to the Arcules cloud service directly from their on-premise XProtect system.
“The Arcules-XProtect Hybrid VMS Solution is an ideal solution for businesses looking to expand their surveillance operation across geographically dispersed locations,” said Arcules CEO Andreas Pettersson. “These businesses can enjoy the strong capabilities of on-premise VMS while reducing their capital investment. The solution also enables organizations to better manage their operational costs as a result of flexible pricing schemes and minimal hardware requirements.”
The Arcules-XProtect Hybrid VMS Solution regional availability outside of North America and Europe is based on market demand conditioned by datacenter availability and/or the possibility to utilize data centers in other regions.
Arcules will demonstrate the solution in booth #809 at the MIPS 2020 Conference , February 17-19, at the Gaylord Texan in Grapevine, TX as well as in Arcules booth #31081 and Milestone booth #18053 during the 2020 ISC West Conference and Expo , March 17-20, at the Sands Expo in Las Vegas.
About Arcules
Arcules, a Canon Group company, addresses the unmet need of modern enterprises for integrated cloud-based video surveillance, access control and analytics. Using the latest developments in cloud, artificial intelligence and machine learning, Arcules combines previously untapped video monitoring data with sensor data and analytics to deliver actionable insights that ultimately drive better business decisions, optimize operations and improve safety. Arcules is headquartered in Irvine, Calif. Visit www.arcules.com for more information and follow us on LinkedIn , Facebook , and Twitter .
About Milestone Systems
Milestone Systems is a leading provider of open platform video management software; technology that helps the world see how to ensure safety, protect assets and increase business efficiency. Milestone enables an open platform community that drives collaboration and innovation in the development and use of network video technology, with reliable and scalable solutions that are proven in more than 500,000 installations worldwide. Founded in 1998, Milestone is a stand-alone company in the Canon Group. For more information visit: http://www.milestonesys.com . For news and other press releases, visit our Newsroom . Click here for information on Trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005274/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom